Please login to the form below
ulcerative colitis
This page shows the latest ulcerative colitis news and features for those working in and with pharma, biotech and healthcare.
Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
The FDA approval covers adult patients with forms of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.
Latest news
-
J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
When it came the US approval covered six indications, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis and Crohn's disease.
-
BMS’ Zeposia gains FDA approval in ulcerative colitis
to severely active ulcerative colitis (UC). ... We’re thrilled that our pursuit of transformative science in immunology may benefit patients in their ulcerative colitis treatment by introducing a new option that has a different mechanism of action
-
Lilly reports positive data from its phase 3 ulcerative colitis trial
Eli Lilly’s IL-23 blocker mirikizumab has hit the mark in a phase 3 study in ulcerative colitis (UC), helping patients to achieve clinical remission 12 weeks after initiating treatment. ... Skyrizi is also being evaluated in a phase 2/3 trial for
-
Merck to acquire Pandion Therapeutics for $1.85bn
the potential treatment of ulcerative colitis and other autoimmune diseases. ... of systemic lupus erythematosus and ulcerative colitis.
-
FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
It is also approved to treat patients with psoriatic arthritis who have not responded well to prior methotrexate treatment and ulcerative colitis.
J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
BMS’ Zeposia gains FDA approval in ulcerative colitis
Lilly reports positive data from its phase 3 ulcerative colitis trial
Merck to acquire Pandion Therapeutics for $1.85bn
FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
More from news
Approximately 21 fully matching, plus 128 partially matching documents found.
Latest Intelligence
-
Setting up for success in a post-Brexit, post-pandemic Britain
With a focus on inflammatory and fibrotic conditions, we have submitted a marketing application through our partnership with Gilead for a new treatment for ulcerative colitis (UC) to the MHRA in
-
Gut instincts lead Takeda to GI pipeline success
with Crohn’s disease or ulcerative colitis is expected to rise by around 25% by 2025, according to recent studies.
-
A snapshot of Microbiotica
These capabilities attract collaborations with leading groups from around the world to provide the clinical data and samples to feed the process, including a University of Adelaide ulcerative colitis FMT study. ... We know this has had an impact.
-
Taking a lean and careful approach
ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
-
Making digital health personal
Personalisation: A case study. This case study is of a digital health support programme that improved persistence of people with ulcerative colitis.
Setting up for success in a post-Brexit, post-pandemic Britain
Gut instincts lead Takeda to GI pipeline success
A snapshot of Microbiotica
Taking a lean and careful approach
Making digital health personal
More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest appointments
-
Lorin Johnson joins Atlantic Healthcare board
Atlantic's lead asset, alicaforsen for the treatment of the inflammatory bowel diseases ulcerative colitis and pouchitis.
-
Ex J&J VP joins board of Immune
Its lead product candidate is bertilimumab, which is in clinical development for ulcerative colitis and Crohn's Disease as well as the rare skin condition bullous pemphigoid.
-
AstraZeneca veteran Deborah Hartman joins Avaxia
Will lead the development of AVX-470 in ulcerative colitis. Former AstraZeneca (AZ) vice president Dr Deborah Hartman has joined Avaxia Biologics as VP research, replacing Dan Tracey who retires. ... with active ulcerative colitis.
-
EMA’s Pharmacovigilance Risk Assessment Committee gains new members
Their respective alternates are Kirsten Myhr, from the Norwegian Board of Health, and Marco Greco, from the European Federation Crohn's and Ulcerative Colitis Associations.
Lorin Johnson joins Atlantic Healthcare board
Ex J&J VP joins board of Immune
AstraZeneca veteran Deborah Hartman joins Avaxia
EMA’s Pharmacovigilance Risk Assessment Committee gains new members
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Insights from patients during the COVID-19 pandemic
We carried out a survey among patients who have any one of these conditions: chronic obstructive pulmonary disorder (COPD), ulcerative colitis (UC), Crohn’s disease (CD) and idiopathic pulmonary fibrosis (IPF).
-
July 2020: diversity and inclusion in clinical trials round-up
Although there’s been an increase of inflammatory bowel disease (IBD) in underrepresented populations, there are still lots of misconceptions surrounding Crohn’s and ulcerative colitis among certain ethnic groups. ... Different ethnic groups are at
-
News: Living with Ulcerative Colitis and Crohn's Disease
Living with Ulcerative Colitis (UC) and Crohn’s Disease (CD) are new patient syndicated reports which offer valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs.
-
Cello Health Insight wins EphMRA’s 2019 Market Research Excellence Award for 'Business Impact through Innovation'
The winning entry focused on exploring the Crohn’s Disease and Ulcerative Colitis patient journeys – mapping the transactional touchpoints and overlaying the emotional experience of patients so that Janssen could gauge
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease,
Insights from patients during the COVID-19 pandemic
July 2020: diversity and inclusion in clinical trials round-up
More from PMHub
Approximately 5 fully matching, plus 10 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
-
CEO Pricing & Market Access, UK
-
Six figure salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
CEO, Head of Health, UK
-
Six figure salary
- Valneva COVID-19 vaccine more effective than AZ
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s COVID-19 antiviral under review in Europe by EMA
- AZ’s Imfinzi boosts survival in biliary tract cancer
- MAKING THE FIRST YEAR MATTER
- Merck receives first breast cancer approval in Europe for Keytruda
- Benefits of COVID-19 vaccine in younger children outweigh risks, says FDA
- Call for industry innovators to join working group
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
- Curb your conservatism: can pharma ditch its cautious approach to creativity in comms?
- Amgen strikes $240m autoimmune deal with Evoq Therapeutics
- Award-winning health agency 90TEN launches in the US
PMHub
W2O Group
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...
Latest intelligence
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
- Towards Better HCP Engagement – An Email Masterclass
- 6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....
